{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257368","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-06-04T20:05:17+00:00","discovered_at":"2026-06-04T20:06:00.289247+00:00","generated_at":"2026-06-04T20:06:37.037955+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kura Oncology stockholders approve 6.5M share increase for equity plan and 2.5M for ESPP at annual meeting","bullets":["Stockholders approved amendment to 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.","Stockholders approved amendment to 2015 ESPP, increasing authorized shares by 2.5 million.","Elected three Class III directors: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. to terms expiring 2029.","Ratified Ernst & Young as independent auditor for FY2026; 69.4M for, 140.8K against.","Advisory Say-on-Pay approved (48.8M for, 1.1M against); board set future votes every year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257368","json":"https://secwatch.observer/filing/0001193125-26-257368.json","markdown":"https://secwatch.observer/filing/0001193125-26-257368.md","text":"https://secwatch.observer/filing/0001193125-26-257368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/kura-20260604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:06:37.037955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6085ae6e7b4054fa0ab0ab0b9e35342a3851a1c1","claim":"Kura Oncology, Inc. shareholders approved Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation at the 2026-06-04 meeting.","evidence_excerpt":"Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation 1 Year 2 Years 3 Years Abstain Broker Non-Votes 48,362,762 54,055 1,586,672 8,677,543 11,097,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"6c2a87d77378a4384e66baeb53b1e4045c8174fd","claim":"Kura Oncology, Inc. shareholders approved Approval of our Amended ESPP at the 2026-06-04 meeting.","evidence_excerpt":"Proposal 6. Approval of our Amended ESPP For Against Abstain Broker Non-Votes 58,306,174 213,434 161,424 11,097,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"96a4b28bdf78cedaf0261b1617cc437e7a62593d","claim":"Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2026-06-04 meeting.","evidence_excerpt":"Proposal 1. Election of Directors Name of Director Elected For Withheld Broker Non-Votes Diane Parks 44,060,724 14,620,308 11,097,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"9cdea61bb769719dd48b843b2fd4117393182902","claim":"Kura Oncology, Inc. shareholders approved Approval of our Amended 2014 Plan at the 2026-06-04 meeting.","evidence_excerpt":"Proposal 5. Approval of our Amended 2014 Plan For Against Abstain Broker Non-Votes 48,402,820 10,099,296 178,916 11,097,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"9f7960c53f5526f8864946433af649b674fabc51","claim":"Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.","evidence_excerpt":"Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes 48,783,834 1,141,854 8,755,344 11,097,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"},{"claim_id":"cc83f24ad9a0bc9f584b00144be765ddb9d72b50","claim":"Kura Oncology, Inc. shareholders approved Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2026-06-04 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 69,385,497 140,763 252,320 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-04"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}